Herz Und Diabeteszentrum NRW Bad Oeynhausen Universitaetsklinik Der Ruhr-Universitaet Bochum
- Address
- lock Available on a paid plan
Cardiovascular Disease Research
The Institute of Anesthesiology and Pain Therapy at the Herz Und Diabeteszentrum NRW is conducting studies aimed at reducing heart‑related events, lowering harmful cholesterol levels, and improving outcomes after cardiac procedures.
- Heart failure prevention
- LDL‑cholesterol lowering therapies
- Lipoprotein(a) reduction strategies
- Major adverse cardiovascular event (MACE) reduction
- Acute kidney injury risk after cardiac surgery
These trials combine advanced imaging, biomarker analysis, and patient‑reported outcomes to evaluate new therapeutic options for people at high cardiovascular risk.
Metabolic & Obesity Studies
Researchers are testing innovative approaches to achieve sustainable weight loss and improve metabolic health in individuals with obesity, overweight, and related conditions.
- Weight reduction interventions
- Combination therapies for obesity
- Metabolic syndrome management
- Impact on cardiovascular outcomes
- Safety of new weight‑loss agents
The program emphasizes both efficacy and quality‑of‑life improvements, targeting patients with or without type 2 diabetes.
Diabetes & Neuropathy Trials
The site is evaluating novel insulin formulations and adjunctive medicines to enhance glycemic control in type 1 diabetes and type 2 diabetes, while also addressing painful diabetic peripheral neuropathy.
- Glycemic control with novel insulins
- Pain relief for diabetic neuropathy
- Renal protection in diabetes
- Combination of SGLT2 inhibitors with other agents
- Long‑term safety of insulin analogues
Outcomes include blood‑sugar metrics, kidney function, and patient‑reported pain relief.
Hypertrophic Cardiomyopathy Research
Studies focus on both obstructive and non‑obstructive hypertrophic cardiomyopathy, testing agents that may improve heart muscle function and patient symptoms.
- Symptom improvement
- Exercise capacity enhancement
- Cardiac imaging outcomes
- Quality‑of‑life measures
- Safety of myosin inhibitors
Researchers use imaging, functional tests, and questionnaires to assess therapeutic benefit.
Kidney Disease & AKI Prevention
Ongoing trials aim to slow progression of chronic kidney disease and prevent acute kidney injury in patients undergoing major cardiac surgery.
- Slowing CKD progression
- Preventing AKI after cardiac procedures
- Blood pressure management in CKD
- Renal outcomes with novel agents
- Biomarker monitoring for kidney health
The work integrates renal function testing with cardiovascular risk assessment to protect kidney health.
Reproductive & Urinary Health Studies
Research includes treatment of polycystic ovary syndrome and evaluation of maternal oxygen therapy to support fetal heart development in high‑risk pregnancies.
- Menstrual irregularity treatment
- Weight‑related PCOS management
- Maternal oxygen therapy for fetal heart development
- Hormonal regulation strategies
- Safety of interventions during pregnancy
These projects address both endocrine balance and fetal cardiovascular outcomes, offering new options for women of reproductive age.
Pain Management in Metabolic Disease
A dedicated program evaluates novel agents to relieve pain associated with diabetic peripheral neuropathy, aiming to improve daily functioning and overall well‑being.
- Novel analgesic agents
- Quality‑of‑life assessments
- Safety profile evaluation
- Dose‑response studies
- Impact on daily functioning
The trials combine patient‑reported outcomes with objective pain measurements to determine therapeutic value.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 38 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
- 1AstraZeneca AB6active
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB10trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Herz Und Diabeteszentrum NRW Bad Oeynhausen Universitaetsklinik Der Ruhr-Universitaet Bochum
lock Showing 1 of 43 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multi- center, randomized, double-blind, placebo-controlled parallel–group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated Lipoprotein(a) | Novartis Pharma AG | Phase II | Not Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 38 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azd5004 | 5 | Unknown | 2024-12-11 | 2024-12-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.